Skip to main content
S

Shandong Pharmaceutical Glass Co.,Ltd — Investor Relations & Filings

Ticker · 600529 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,439 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600529

About Shandong Pharmaceutical Glass Co.,Ltd

Shandong Pharmaceutical Glass Co., Ltd. specializes in the research, development, and manufacturing of glass packaging materials. The company’s product portfolio includes molded glass bottles, tubular glass vials, glass ampoules, and glass cartridges, alongside complementary components such as butyl rubber stoppers and aluminum-plastic caps. These products are engineered to meet international quality standards for the storage and delivery of injectable drugs, oral liquids, and various healthcare products. Utilizing advanced production technologies, the firm provides comprehensive packaging solutions to the pharmaceutical, food, and cosmetic sectors. Its operations focus on maintaining high chemical resistance and structural integrity across its glass containers to ensure product safety and stability.

Recent filings

Filing Released Lang Actions
山东省药用玻璃股份有限公司关于马来西亚全资子公司完成注册登记的公告
Regulatory Filings
2026-04-24 Chinese
山东省药用玻璃股份有限公司第十一届董事会第八次会议决议公告
Regulatory Filings
2026-04-24 Chinese
山东省药用玻璃股份有限公司2026年第一季度报告
Regulatory Filings
2026-04-24 Chinese
山东省药用玻璃股份有限公司关于2025年度“提质增效重回报”行动方案的评估报告暨2026年度行动方案的公告
Regulatory Filings
2026-04-24 Chinese
山东省药用玻璃股份有限公司第十一届董事会审计委员会2026年第四次会议关于第十一届董事会第八次会议相关议案的审核意见
Regulatory Filings
2026-04-24 Chinese
中信证券股份有限公司关于山东省药用玻璃股份有限公司详式权益变动报告书之财务顾问核查意见（修订稿）
M&A Activity Classification · 1% confidence The document is a lengthy, formal “financial advisor verification opinion” on the “detailed equity change report” (“详式权益变动报告书”) for a share subscription/acquisition by two parties of Shandong Medicinal Glass Co., Ltd. It repeatedly cites takeover regulations (e.g., 《上市公司收购管理办法》), provides due diligence findings, governance, funding sources, impact on the listed company, and other sections typical of an M&A/acquisition filing. This is not a simple regulatory announcement or dividend notice, nor is it an annual or interim report. It is directly tied to a takeover/share acquisition event and belongs to M&A Activity (TAR).
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.